Free webinar: Bladder cancer updates from the second half of 2026

ESMO 2026: Bladder and kidney cancer roundup

ESMO 2026: Prostate cancer roundup

Outpatient administration of xaluritamig for mCRPC: Feasibility and safety

Personalised neoantigen vaccine plus radiotherapy improves progression free survival in advanced solid tumours

Tarlatamab improves long term survival in previously treated small cell lung cancer

Mocertatug rezetecan shows promising activity in platinum-resistant ovarian cancer

ABBV-706 shows promising antitumour activity in R/R SCLC

Arcotatug tavatecan improves progression-free survival in CLDN18.2-positive advanced gastric cancer

Zanidatamab plus chemotherapy improves overall survival in HER2-positive advanced gastroesophageal cancer

STRIDE-based immunotherapy plus TACE shows promising outcomes in embolisation-eligible HCC

Darolutamide plus ADT and radiotherapy improves metastasis free survival in very high risk prostate cancer

ESMO 2026: Surgery in high-risk localised prostate cancer

Omega-3 EPA improves overall survival after colorectal cancer liver metastasis resection

Updated survival and ctDNA findings support adjuvant cemiplimab in high-risk CSCC

Long-term survival benefits of abiraterone in de novo metastatic prostate cancer

Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC

Tarlatamab plus durvalumab improves survival in extensive-stage small cell lung cancer

Real-world outcomes with tarlatamab in previously treated ES-SCLC

Risvutatug rezetecan improves PFS in relapsed or refractory osteosarcoma

Reduced dosing frequency of immune checkpoint inhibitors raises survival concerns in advanced cancer

Pembrolizumab improves PFS and QoL in dMMR advanced endometrial cancer

Sacituzumab tirumotecan reduces progression and death in recurrent endometrial cancer

ESMO 2026: Highlights and analysis

Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer

Lifileucel plus pembrolizumab shows durable responses in first-line advanced melanoma

T-cell engagers in mAPMR/mCRPC

Short course durvalumab remodels the tumour immune microenvironment in early stage triple negative breast cancer

Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma

Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer

ESMO 2026: Advances in NMIBC and MIBC

Perioperative apalutamide plus ADT improves event free survival in high risk localised prostate cancer

AI-based digital MammaPrint assay predicts recurrence risk and survival in early-stage breast cancer

UV1 vaccine combination shows no significant PFS improvement in BRCA wild type recurrent ovarian cancer

HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma

Camupepimut shows early disease free survival signal in resected KRAS mutated pancreatic cancer

TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer

AI tool identifies patients most likely to benefit from extended endocrine therapy in hormone receptor-positive breast cancer

Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results

Perioperative pembrolizumab fails to significantly improve event-free survival in muscle-invasive bladder cancer

Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer